Small-Cap Investor Forum

[MissionIR]

Axsome Therapeutics, Inc. (AXSM) Shedding New Light on Old Drugs

New York-based Axsome Therapeutics, Inc. (NASDAQ: AXSM) is tending to a major and thriving market where current treatment options are insufficient. This young company (founded in 2012) is striving to establish a fully-integrated biopharmaceutical business that will develop and bring to the healthcare marketplace therapies for the management and treatment of central nervous system (CNS) disorders.

Axsome Therapeutics has a laser-like focus on differentiated therapies, in particular. To improve the lives of patients living with pain and various CNS disorders, Axsome has set its sights on working with both internally-derived drug candidates and in-licensed drug candidates in order to create a path to development and commercialization that will, ultimately, expand the treatment alternatives available to caregivers.

Axsome Therapeutics has moved into the clinical stage at this time. It holds a product candidate portfolio that includes two late-stage candidates, AXS-02 and AXS-05, which it is developing for multiple indications, as well as AXS-06.

AXS-02, a non-opiod therapeutic in development for chronic pain, is Axsome’s leading product candidate. It is currently being evaluated in phase III trials for the treatment of complex regional pain syndrome, knee osteoarthritis with bone marrow lesions (BMLs) and chronic low back pain with modic changes.

AXS-05 is a fixed-dose combination of dextromethorphan and bupropion, both of which have shown to be effective in activating central nervous system receptors. AXS-05 is currently in a phase III trial indicated for treatment resistant depression and agitation in patients with Alzheimer’s disease.

The company is also developing AXS-06 for the treatment of chronic pain disorders.

Analysts have pointed to the value in Axsome’s focus on complex regional pain syndrome, treatment resistant depression and agitation in patients with Alzheimer’s disease, indicating that these disorders possess lower-than-average research and development risks and a tested business model that leans toward a faster commercialization timeline (http://dtn.fm/Urt7t).

For more information, visit www.Axsome.com